Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2018
Proposal to list eplerenone for the treatment of heart failure in patients intolerant to spironolactone
24 January 2018 - Following assessment of bids in PHARMAC’s 2017/18 annual Invitation to Tender, PHARMAC is proposing to fund ...
Posted by Michael Wonder on 08 Jan 2018
Significant step forward for treating people with head and neck cancer
21 December 2018 - Funding cetuximab for patients with head and neck cancer will be a significant advance for treating ...
Posted by Michael Wonder on 02 Jan 2018
New Zealand Pharmaceutical Schedule - 1 January 2018
1 January 2018 - The January 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Nov 2017
New Zealand Pharmaceutical Schedule - 1 December 2017
1 December 2017 - The December 2017 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 16 Nov 2017
NZAF welcomes PHARMAC’s milestone proposal to fund pre-exposure prophylaxis
16 November 2017 - In a proposal released this week, PHARMAC has announced its intention to fund the HIV-prevention drug ...
Posted by Michael Wonder on 15 Nov 2017
Proposal to widen funded access to pulmonary arterial hypertension treatments
15 November 2017 - PHARMAC is seeking feedback on a proposal to make several changes to the funding of medicines ...
Posted by Michael Wonder on 14 Nov 2017
Proposal to widen access to various anti-infectives
14 November 2017 - PHARMAC is seeking feedback on three proposals to widen funded access, from 1 January 2018, to ...
Posted by Michael Wonder on 09 Nov 2017
Decision to fund zoster vaccine
9 November 2017 - PHARMAC is pleased to announce the approval of an agreement with Merck Sharpe & Dohme to ...
Posted by Michael Wonder on 08 Nov 2017
Proposal to list methylnaltrexone bromide
8 November 2017 - PHARMAC is seeking feedback on a proposal to list methylnaltrexone bromide (Relistor) 12 mg/0.6 mL injection in ...
Posted by Michael Wonder on 31 Oct 2017
New Zealand Pharmaceutical Schedule - 1 November 2017
1 November 2017 - The November 2017 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 24 Oct 2017
Hundreds of people with diabetes are set to benefit from the funding of a new treatment that will help prevent blindness
24 October 2017 - From 1 November 2017 dexamethasone implants (brand name Ozurdex) will be funded for eligible people with ...
Posted by Michael Wonder on 13 Oct 2017
Decision to fund dexamethasone implants (Ozurdex)
13 October 2016 - PHARMAC is pleased to announce the approval of an agreement with Allergan for the listing of ...
Posted by Michael Wonder on 04 Oct 2017
Proposal to list a range of medical thermometer products and medical devices used in the prevention of venous thromboembolisms supplied by Medtronic
4 October 2017 - PHARMAC is seeking feedback on a proposal to list a range of medical thermometer and venous thromboembolism ...
Posted by Michael Wonder on 30 Sep 2017
New Zealand Pharmaceutical Schedule - 1 October 2017
1 October 2017 - The October 2017 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 16 Sep 2017
Proposal to fund dexamethasone ocular implants for DMO
15 September 2017 - PHARMAC is seeking feedback on a proposal to list dexamethasone 700 mcg ocular implants (Ozurdex) through ...